Also trades as: SABS (NASDAQ) · $vol 2M
SABSW NASDAQ
SAB Biotherapeutics, Inc.
1W: -50.9%
1M: -34.1%
3M: -54.0%
YTD: -72.6%
1Y: -78.4%
3Y: -83.2%
$0.01
-0.00 (-7.06%)
Weekly Expected Move ±105.3%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.1M
52W Range0.0077-0.0477
Volume13,766
Avg Volume45,665
Beta0.53
Dividend—
Analyst Ratings
Company Info
CEOSamuel J. Reich
Employees86
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-25
Websitesab.bio
2100 East 54th Street North
Miami Beach, FL 33140
US
Miami Beach, FL 33140
US
605-679-6980
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a biopharmaceutical firm specializing in the development of immunotherapies. Their efforts are directed towards combating various health challenges, such as infectious and autoimmune diseases, as well as oncology. Among their notable therapeutic candidates are SAB-142, an anti-thymocyte globulin intended for Type 1 diabetes; SAB-176, which targets seasonal influenza; and SAB-301, developed to counter Middle East Respiratory Syndrome Coronavirus (MERS-COV). Founded in 2014, the company's headquarters are located in Sioux Falls, South Dakota, with a secondary office situated in Cambridge, Massachusetts.
Latest News
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kropotova Alexandra | F-InKind | 988 | — | 2026-03-24 |
| Jain Rita | 0 | — | 2026-01-05 | |
| ZACCARDELLI DAVID | 0 | — | 2026-01-05 | |
| Kropotova Alexandra | F-InKind | 988 | — | 2025-12-11 |
| Moin Andrew | M-Exempt | 17,400 | $1.75 | 2025-09-29 |